Relationship between serum S-100 protein level and ischemic damage degree in patients with acute cerebral infarction

Objective: To investigate the time course of serum S-100 concentrations of patients with acute cerebral infarction,and their relation with the clinical data and the prognosis. Methods: Serum S-100 levels were serially determined in 36 patients with acute cerebral infarction within 12 h, at 24 h and day 2, 3, 4, 5, 7 and 10 after acute cerebral infarction and in 20 age- and sex-matched control subjects. An S-100 content assay was performed using a two-site radioimmunoassay technique. The clinical status was assessed using NIH Stroke Scale. The functional deficit at 4 weeks after acute cerebral infarction was scored using the modified Rankin scale. A cranial computed tomography was performed initially. Results: Elevated concentrations of S-100 (>0.2 μg/L) were observed in 29 of 36 patients with acute cerebral infarction,but none of the control subjects. The S-100 peak levels were at day 2 and 3 after acute cerebral infarction and were significantly high in those patients with severe neurological deficit at admission, with extensive infarction or with space-occupying effect of ischemic edema as compared with the rest of the populations. Conclusion: Serum S-100 level assay can be used as a peripheral marker of ischemic brain damage, and may be helpful for evaluation of therapeutic effects in acute ischemic stroke.

Effects of Maixuekang Capsules Combined with Edaravone on Serum MMP-9, S-100β Protein Levels and Neurological Functions in Patients with Hemorrhagic Cerebral Infarction

OBJECTIVE: To investigate the effects of Maixuekang Capsules combined with edaravone on serum matrix metalloproteinase-9(MMP-9), S-100β protein levels and neurological functions in patients with hemorrhagic cerebral infarction. METHOSDS: A total of 76 patients with hemorrhagic cerebral infarction treated in the First Affiliated Hospital of Henan University of Science and Technology from January 2017 to May 2018 were selected and were randomly divided into treatment group and control group, with 38 patients in each group. The control group was given edaravone, and the treatment group was given Maixuekang Capsules on the basis of the control group. The clinical efficacy, serum MMP-9 and S-100β protein levels, neurological function recovery, activity of daily living and incidence rate of adverse reactions were compared between the 2 groups. RESULTS: The total effective rate of the treatment group was 92.11%, which was higher than 71.05% of the control group(P < 0.05); the National Institutes of Health Stroke Scale(NIHSS) score in the 2 groups decreased(P < 0.05), and the Activity of Daily Living Scale(ADL) score increased(P < 0.05), the improvement of the above 2 scores in the treatment group were better than those in the control group(P < 0.05); the level of MMP-9 was gradually decreasing in the 2 groups, on the 7th day, 14 th day after treatment, and the levels of MMP-9 decreased significantly(P < 0.05), and the treatment group was lower than the control group at all time points(P < 0.05); on the 3rd day after treatment, the levels of S-100β protein in the 2 groups increased significantly(P < 0.05); on the 7th day, 14 th day after treatment, the levels of S-100β protein in the two groups decreased significantly(P < 0.05), and the treatment group was significantly lower than the control group(P < 0.05); there was no significant difference in incidence rate of adverse reactions between 7.89% in the control group and 5.26% in the treatment group(P > 0.05). CONCLUSION: The combination of Maixuekang Capsules and edaravone is effective in treating hemorrhagic cerebral infarction, and it can significantly improve neurological function defect and daily living ability, reduce serum MMP-9 and S-100β protein levels, and has higher safety.

Comparison of plasma NSE, protein S-100b and EEG changes in traditional arrested-heart procedures and on-pump beating-heart procedures

Objective: To assess the cerebral injury in on-pump beating-heart procedures under mild hypothermia in comparison with traditional on-pump arrested-heart procedures under moderate hypothermia. Methods: Forty patients, 20 with congenital heart disease (CHD) and 20 of rheumatic heart disease (RHD) , were divided into 2 groups: Control group (group A, n =20) including 10 patients suffering from CHD as group Al and the left 10 from RHD as group A2; and experiment group (group B, n =20) which consisting of group B1 (10 with CHD) and group B2 (10 of RHD). The patients in group A underwent traditional arrested-heart procedures, and those in group B were operated on with beating-heart procedures. Arterial blood samples were collected at preoperation (time A) , 20 min after cardiopul-monary bypass (CPB) starting (time B) , 1 h after CPB (time C) and 24 h postoperation (time D) respectively. Plasma contents of neuron-specific enolase (NSE) and protein S-100b were measured with sensitive ELISA. All the patients received echoencephalography (EEG) before and 1 week after operation. Results: The plasma contents of protein S-lOOb were increased very significantly at time B, C and D in comparison with those at time A (P<0.01) , and that of patients in group Al was significantly higher than that in group B at time B (P < 0. 05 ). There was no significant difference at other time points. At time B, the plasma contents of NSE were significantly higher in group A than in group B, and in group Al and Bl than in group A2 and B2. What's more, at time B, the former fell back to their pre-operative levels, but the latter remained still higher levels than the preoperative ones ( P < 0.01). No significant difference was found in the abnormality rates of postoperative EEG between 2 groups. Conclusion: The perioperative plasma contents of NSE and protein S-100b are not significantly higher in group B than in group A. On-pump beating-heart procedures do not make more serious cerebral dysfunction than the traditional arrested-heart procedures.

Effects of sodium valproate combined with levetiracetam in treatment of children epilepsy and its influences on serum S-100βand high mobility group box-1

Objective:To explore the effects of sodium valproate combined with levetiracetam in the treatment of children epilepsy,and its influences on serum S-100βand high mobility group box-1(HMGB-1)in children with epilepsy.Methods:A total of 160 children who were diagnosed as epilepsy in Baogang Hospital of Inner Mongolia from July 2016 to October 2018 were selected as research objects.They were randomly divided into the study group(n=80)and the control group(n=80)by the random number table method,i.e.,they were treated with sodium valproate combined with levetiracetam and sodium valproate alone,respectively.After 16 weeks of treatment,the effective rates of epileptic seizure treatment and the improvement of epileptiform discharge were evaluated,and chi-square test was used for statistical comparison.The related indicators,including serum tumor necrosis factor-(TNF-α),hypersensitive C-reactive protein(hs-CRP),homocysteine(Hcy),haematocrit(HCT),erythrocyte sedimentation rate(ESR),serum S-100βand HMGB-1,were measured before and after treatment.Paired t-test was used for the comparison in the above indicators within a group before and after treatment;group t-test was used for the comparison between two groups.Chi-square test was used for the comparison in the rate of adverse reactions during treatment between two groups.The study was approved by Ethics Committee of Baogang Hospital(Approval No.:BG201606073),and all children’s guardians were required to sign informed consent forms for clinical study.There were no statistically significant differences between two groups in general clinical data(p>0.05),such as sex constituent ratio,age,the course of disease,the frequency of epileptic seizure per year before treatment,the incidence of epileptiform discharge before treatment and the constituent ratio of types of epileptic seizure,etc.Results:1)After treatment,the effective rates of epileptic seizure treatment and the improvement of epileptiform discharge in the study group were 92.5%(74/80)and 85.0%(68/80)respectively,which were both significantly higher than those in the control group[68.8%(55/80)and 58.8%(47/80)],and the differences were statistically significant(Х^(2)=14.444,13.635;p<0.001).2)In the study group,the levels of serum TNF-α,hs-CRP and Hcy,as well as HCT and ESR after treatment were(53.1±14.0)pg/ml,(5.0±2.5)mg/L,(12.5±3.1)μmol/L,(38.1±5.1)%and(3.0±0.5)mm/h respectively,which were all significantly lower than those[(107.9±17.8)pg/ml,(10.1±2.5)mg/L,(42.2±5.8)μmol/L,(45.3±4.5)%and(5.2±0.6)mm/h]before treatment,and all the differences were statistically significant(t=21.644,12.902,40.393,9.468,25.194;p<0.001).In the control group,the levels of serum TNF-α,hs-CRP and Hcy,as well as HCT and ESR after treatment were(60.6±17.8)pg/ml,(8.2±2.2)mg/L,(15.2±3.1)μmol/L,(40.2±3.4)%and(4.5±0.6)mm/h respectively,which were all significantly lower than those[(112.4±14.3)pg/ml,(9.3±3.8)mg/L,(41.1±2.8)μmol/L,(44.6±5.5)%and(5.4±0.8)mm/h]before treatment,and all the differences were statistically significant(t=20.292,2.241,55.456,3.320,8.050;p<0.05).After treatment,the above indicators in the study group were all significantly lower than those in the control group,and all the differences were statistically significant(t=2.962,8.595,5.508,3.064,17.178;p<0.05).3)In the study group,the levels of serum S-100βand HMGB-1 after treatment were(0.65±0.38)μg/L and(5.3±2.4)μg/L respectively,which were significantly lower than those[(0.91±0.32)μg/L and(8.1±2.0)μg/L]before treatment,and the differences were statistically significant(t=4.681,8.020;p<0.001).In the control group,the levels of serum S-100βand HMGB-1 after treatment were(0.78±0.27)μg/L and(6.4±2.2)μg/L respectively,which were significantly lower than those[(0.88±0.25)μg/L and(7.9±1.7)μg/L]before treatment,and the differences were statistically significant(t=2.431,p=.016;t=4.826,p<0.001).After treatment,the levels of serum S-100βand HMGB-1 in the study group were significantly lower than those in the control group,and the differences were statistically significant(t=2.495,p=.014;t=2.840,p=.005).4)There was no significant difference between two groups in the rate of adverse reactions,such as nausea,vomiting,poor appetite,dizziness,drowsiness,hepatic and renal injury during treatment(p>0.05).Conclusions:The efficacy of sodium valproate combined with levetiracetam is obviously better than that of sodium valproate alone in the treatment of children epilepsy.The children patients’serum S-100βand HMGB-1 are more significantly reduced,resulting in a lower rate of adverse reactions,which has a certain clinical value.

完全性脊髓损伤后血清S-100β蛋白浓度的变化

目的评价S-100β蛋白能否成为创伤性脊髓损伤的血清标记物。方法 2013年6月~2014年10月,选取完全性脊髓损伤患者24例,分别在损伤后1周、3个月、6个月抽血,采用酶联免疫吸附法测定血清中S-100β蛋白浓度,以10名健康人血清作为正常对照。结果 S-100β蛋白血清浓度在损伤后1周、3个月时显著升高（Z〉4.273,P〈0.001）。结论 S-100β蛋白血清浓度升高可能有助于评估完全性脊髓损伤后早期的组织损伤。

病毒性脑炎患儿脑脊液和血清S-100β蛋白测定的意义

目的探讨病毒性脑炎(病脑)患儿脑脊液(CSF)和血清S-100β蛋白变化的临床意义。方法采用酶联免疫吸附试验双抗体夹心法对36例病脑和20例无神经系统疾病而需外科手术的腰麻患儿CSF和血清S-100β蛋白进行测定。比较昏迷组与无昏迷组、惊厥组与无惊厥组、有后遗症组与无后遗症组CSF和血清S-100β蛋白水平的差异。结果 1．病例组和对照组CSF 中S-100β蛋白水平分别为(0.641±0．390)、(0．037±0．014)μg/L,血清S-100β蛋白水平分别为(0．444±0．257)、(0．023± 0．009)μg/L,两组CSF、和血清S-100β蛋白水平均有显著性差异(P<0．01,0．05);昏迷组CSF和血清S-100β蛋白均显著高于无昏迷组(P均<0 01);惊厥组CSF和血清S-100β蛋白水平均高于无惊厥组(P均<0．01);后遗症组CSF和血清S-100β蛋白均高于无后遗症组(P均<0．01)。结论病脑患儿CSF和血清S-100β蛋白水平与疾病严重程度相关,检测病脑患儿S-100β蛋白水平的变化,有助于判定脑组织受损的严重程度及评估患儿的预后。

癫患儿血清S-100β、胶质纤维酸性蛋白变化的意义

目的探讨癫发作患儿及治疗后血清S-100β、胶质纤维酸性蛋白(GFAP)的变化。方法采用双抗体夹心酶联免疫吸附法对41例癫患儿在癫发作24h内、用药4、12周分别进行定量测定其血清S-100β、GFAP蛋白水平,并与30例健康儿童进行比较。采用SPSS11.0软件进行分析。结果发作后24h:癫组患儿血清S-100β、GFAP蛋白水平均显著高于对照组(Pa<0.01);婴儿痉挛症组血清S-100β、GFAP蛋白水平明显高于其他各组(Pa<0.01);局限性发作与全面性发作组比较,2组S-100β、GFAP蛋白水平无显著性差异(P>0.05)。用药后4周:癫组血清S-100β、GFAP水平较前明显下降,但仍高于健康对照组(P<0.01)。用药后12周:根据癫控制标准,控制23例,显效12例,有效4例,无效2例;各组S-100β、GFAP蛋白水平明显下降,无效组与其他各组比较,S-100β、GFAP蛋白水平仍高(P<0.05);其余各组比较无显著差异。癫患儿血清S-100β、GFAP蛋白水平经直线相关分析呈高度正相关(r=0.54P<0.01)。结论血清S-100β、GFAP水平在发作后癫患儿明显升高,临床控制效果与S-100β、GFAP蛋白水平高低、下降速度有关,二者可作为早期预测脑损伤、损伤程度并判断预后的指标之一。

重型颅脑损伤患者血清S-100β、C-反应蛋白动态水平变化及其临床意义研究

目的:分析研讨重型颅脑损伤患者血清S-100β、C-反应蛋白(CRP)动态水平变化及其临床意义。方法:此次讨论中所研讨的96例患者均随机从2014年5月-2016年5月本院收治的重型颅脑损伤患者中筛选而出,入院时根据GCS(格拉斯哥昏迷评分)将98例患者分为重型组和特重型组,另选取43例正常体检者设为对照组。应用ELISA(酶联免疫吸附法)检测血清中S-100β浓度,应用蛋白分析仪来检测CRP的浓度。结果:特重型组和重型组颅脑外伤患者血清S-100β及CRP的含量均明显高于对照组,差异均有统计学意义(P<0.05);特重型组患者血清S-100β含量明显高于重型组,差异有统计学意义(P<0.05);特重型组患者血清CRP含量与重型组比较,差异无统计学意义(P>0.05);三种不同类型颅脑损伤的血清S-100β含量比较,差异均有统计学意义(P<0.05);三种不同类型颅脑损伤的血清CRP含量比较,差异均无统计学意义(P>0.05);患者入院后第2天血清S-100β及CRP的含量值达到峰值,血清S-100β在7 d内下降迅速,逐渐接近正常;血清CRP在7 d内下降缓慢。结论:重型颅脑损伤患者入院初期血清S-100β及CRP水平增高与疾病的出现密切相关。CRP检测值不能够完全区分脑损伤类型及程度。血清S-100β可作为判定脑损伤的指标,血清S-100β含量越高表明脑损伤程度越严重,并且能够将脑损伤类型区分出,可以为治疗及预后评估提供理论依据,具有临床推广及应用价值。

脑出血患者血清S-100β蛋白的动态变化及其意义

目的:探讨脑出血患者血清S-100β蛋白含量的动态变化及其意义。方法:采用酶联免疫吸附试验双抗体夹心法对21例脑出血患者在发病后的第1天、第3天及第5天的血清S-100β蛋白含量进行了动态的监测,并与脑出血量及神经功能缺损评分进行相关分析。结果:①患者第1天的血清S-100β蛋白含量高于对照组(P<0.01),但第3天、第5天分别与对照组间差异均无显著性(P>0.05)。②脑出血患者血清平均S-100β蛋白含量的峰值出现在脑出血后的第1天。③脑出血后的第1天血清S-100β蛋白含量与出血量相关(r=0.697,P=0.001)。④脑出血后的第1天血清S-100β蛋白含量与神经功能缺损评分相关(r=0.525,P=0.025)。结论:血清S-100β蛋白能作为反映脑出血患者病情严重程度的一个指标。

双抗体夹心法检测血清S-100蛋白及其临床意义

目的 :为研究血清中S 1 0 0蛋白与脑组织病变的关系。方法 :采用S 1 0 0蛋白单克隆抗体为包被抗体和抗S 1 0 0多克隆抗体为检测抗体的双抗体夹心ELISA方法 ,检验神经系统损伤及脑肿瘤组与正常对照组 (无神经系统损伤、无肿瘤 )的血清中S 1 0 0的含量。结果 :神经系统损伤患者S 1 0 0蛋白大多 >0 .1 5 μg·L-1 ,正常对照组 <0 .1 5 μg·L-1 ,差别有显著性。结论 :S 1 0 0蛋白可作为衡量脑组织病变 (脑损伤、脑肿瘤 )的一个临床指标 。

血清S-100蛋白、NSE在早产儿脑损伤中的早期诊断价值

目的探讨血清S-100蛋白、神经元特异性烯醇化酶(NSE)水平与早产儿脑损伤的关系。方法 94例符合条件的早产儿随机分为有脑损伤的实验组(49例)和无脑损伤的对照组(45例),采用ELISA法分别在早产儿出生后24 h内及7 d后对比检测实验组和对照组早产儿血清的S-100蛋白、NSE水平。结果实验组出生后24 h内及7 d后其血清S-100蛋白、NSE水平均明显高于对照组,差异具有统计学意义(P<0.05)。脑损伤患儿的血清S-100蛋白及NSE改变明显早于影像学改变。结论血清S-100蛋白、NSE水平能较早的反映早产儿脑损伤及其严重程度,对早产儿脑损伤的早期诊断有较高的价值。

S-100 b蛋白在小儿病毒性脑炎病情判断和预后评估中的价值

目的观察病毒性脑炎急性期和恢复期脑脊液(cerebrospinal fluid,CSF)和血清中S-100 b蛋白含量的变化,探讨S-100 b在病毒性脑炎病情判断和预后评估的临床应用价值。方法选择46例病毒性脑炎患儿为观察组,又分为昏迷组(15例)和无昏迷组(31例),20例无神经系统疾病、需行外科腰麻的患儿作为对照组,采用双抗体夹心ELISA法检测急性期、恢复期CSF和血清中S-100 b蛋白含量,进行比较和动态观察。结果①观察组CSF和血清中S-100 b蛋白明显高于对照组(P<0.01);②昏迷组CSF和血清中S-100 b蛋白明显高于无昏迷组(P<0.01);③观察组急性期CSF和血清中S-100 b蛋白水平明显高于恢复期(P<0.01);④CSF中S-100 b蛋白含量与其血清含量呈正相关(r=0.746,P=0.05)。结论CSF和血清中S-100 b蛋白的含量与病毒性脑炎脑损伤程度正相关,对病毒性脑炎的病情判断和预后评估具有重要的临床价值。

探讨急性脑血管病患者血清及脑脊液中S-100β蛋白水平变化及临床意义

目的探讨急性脑血管病患者不同病情程度血清及脑脊液(CSF)中S-100β蛋白动态检测中的临床意义,为早期认知功能评估及治疗提供理论依据。方法自2013年5月—2015年4月,整群选取该院采用荧光免疫测定方法(FIA)测定157例患者(患者组),其中缺血性中风组89例、出血性中风组68例在不同病情程度血清S-100β蛋白的水平变化,同时测定100名健康查体者(对照组)血清及CSF中S-100β蛋白的含量变化。结果缺血性中风组血清及CSF中S-100β蛋白分别为(2.89±1.51)、(4.31±1.92)μg/L,出血性中风组血清及CSF中S-100β蛋白(μg/L)分别为(3.67±1.75)、(6.01±2.13)μg/L;对照组血清及CSF中S-100β蛋白分别为(0.195±0.081)、(3.05±0.418)μg/L。急性脑血管病患者组与对照组血清及CSF中S-100β蛋白含量差异有统计学意义(P<0.001)。不同病情缺血性中风患者(轻度、中度、重度)和出血性中风组(轻度、中度、重度)组内之间血清中及CSFS-100β蛋白的水平变化差异有统计学意义(P<0.001)。结论测定急性脑血管病患者血清及CSF中S-100β蛋白含量变化,对急性脑血管疾病早期诊断及康复治疗提供理论依据,具有重要的临床研究和应用价值。

BNP、Scr、S-100β蛋白及CysC对体外循环心脏手术患者预后的影响

目的探讨脑钠肽(brain natriuretic peptide,BNP)、血清肌酐(serum creatinine,Scr)、S-100β蛋白及胱抑素C(cystatin C,CysC)对体外循环心脏手术预后的影响。方法选取2014年1月1日至2016年1月1日胸外科胸外科诊断为心力衰竭并接受体外循环(extracorporeal circulation,ECC)心脏手术的130例患者为研究对象,自出院后1周进行为期2年的随访。根据随访结果,将患者分预后良好组和预后不良组,运用Kaplan-Meier生存曲线分析体外循环心脏手术患者生存状态;单因素、多因素COX比例风险回归模型分析可能影响ECC心脏手术预后的因素;绘制ROC曲线比较各因素的敏感性及特异性。结果多因素COX比例风险回归模型分析显示S-100β(P=0.025)、Scr(P=0.015)、BNP(P=0.047)、CysC(P=0.008)、LVEF(P=0.037)可影响ECC心脏手术患者预后;CysC联合BNP的ACU为0.846,其敏感性、特异性分别为81.3%,79.05%。结论 S-100β、Scr、BNP、CysC,LVEF是ECC心脏手术预后的影响因素,CysC联合BNP诊断可作为ECC心脏手术的辅助预测指标,具有潜在临床应用价值。

丁苯酞治疗脑梗塞再灌注患者对血清s-100β蛋白、NSE及神经功能缺损情况分析

目的探讨丁苯酞治疗脑梗死再灌注患者对血清s-100β蛋白、NSE及神经功能缺损的影响。方法选取我院于2015年2月至2016年8月收治的早期脑梗塞患者80例为研究对象,按照随机数表法分为两组,研究组40例患者采用尿激酶再灌注手段,对照组40例患者接受包含溶栓在内的常规治疗,而实验组在静脉溶栓治疗的基础上,结合丁苯酞静脉滴注,比较两组患者治疗之后血清s-100β蛋白、NSE及神经功能缺损的变化。结果两组患者溶栓前血清中的s-100β蛋白、NSE、神经功能缺损评分均无显著差异(p>0.05),溶栓后24 h、7 d,血清中的s-100β蛋白含量逐渐下降,溶栓治疗的过程中,血清中的NSE含量开始升高,溶栓治疗结束后,NSE含量随之下降,溶栓治疗后,两组患者神经功能缺损评分明显下降(P<0.05)。结论丁苯酞治疗脑梗死再灌注患者,可显著改善患者血清s-100β蛋白和NSE,有助于神经功能缺损的评分,降低再灌注损伤的发生。

手足口病并发脑干脑炎患儿血清hs-CRP、S-100B蛋白检测的临床意义

C-反应蛋白（C-reactive protein,CRP）是一种急性时相蛋白,在人体发生感染、创伤等情况时会迅速上升,经治疗后又会迅速下降。对观察病情的变化有十分重要的临床价值。S-100B蛋白检测对脑实质性损伤有十分重要的临床价值。

多发性硬化患者血清和脑脊液中S-100b蛋白测定及临床意义

为探讨S 10 0b蛋白与多发性硬化 (MS )临床的关系 ,采用ELISA方法检测 6 0例急性活动期MS ,2 6例对照组血清及脑脊液中S 10 0b含量 ,并进行比较分析。结果发现 ,血清及脑脊液中S 10 0b水平 ,急性活动期MS高于对照组 (P均 <0 0 1) ,MS组血清和脑脊液中S 10 0b含量异常增高者分别为 2 0 %和 96 6 % ;脑脊液S 10 0b水平MS急性活动 7d内高于急性活动 7d以上者 (P <0 0 5 ) ,两者又均高于对照组 (P均 <0 0 1) ;血清S 10 0b水平MS急性活动 7d内高于急性活动 7d以上者及对照组 (P均 <0 0 1) ,急性活动 7d后与对照组比较无差异 (P >0 0 5 ) ;脑脊液S 10 0b水平不同病残程度之间比较无显著性差异 (P >0 0 5 ) ,血清S 10 0b水平在中、重度病残者高于轻度病残者 (P均 <0 0 1) ,重度病残者虽高于中度病残者 ,但差异无显著性意义 (P >0 0 5 )。提示S 10 0b蛋白可作为判断MS疾病活动性及病情严重程度的重要生化标志物之一。

颈动脉内膜剥脱术对缺血性脑卒中患者术后血清GFAP和S-100β水平及生活质量的影响

目的探究颈动脉内膜剥脱术对缺血性脑卒中（AIS）患者术后血清神经胶质纤维酸性蛋白（GFAP）、S-100β水平变化及生活质量的影响.方法选取2014年10月至2016年9月本院84例AIS患者,随机数字表法分组,各42例.对照组予以基础对症治疗,研究组在此基础上予以动脉内膜剥脱术.观察对比两组临床疗效、神经功能评分（NIHSS）、血清GFAP、S-100β水平变化情况、生活质量评分（SF-36）.结果经秩和检验,研究组治疗有效率为90.48%（38/42）,高于对照组的64.29%（27/42）,差异有统计学意义（P〈0.05）;治疗后6个月研究组NIHSS评分低于对照组,差异有统计学意义（P〈0.05）;治疗后6个月研究组血清GFAP、S-100β水平均低于对照组,差异均有统计学意义（均P〈0.05）;治疗后6个月研究组健康状况、精神状态、生理职能、情感职能、躯体疼痛等SF-36评分均高于对照组,差异均有统计学意义（均P〈0.05）.结论颈动脉内膜剥脱术可降低AIS患者术后血清GFAP、S-100β水平,改善神经功能,提高生活质量及治疗效果.

脑梗死患者血清 S-100β蛋白的变化及临床意义

目的：探讨脑梗死患者血清 S‐100β蛋白水平与脑梗死严重程度及脑损伤时间变化趋势的关系。方法对31例重度梗死患者，26例中度梗死患者，28例轻度梗死患者于发病后24 h 、第3 d 、第7 d 和第10 d 采用双抗体夹心酶联免疫吸附试验检测血清 S‐100β水平，对24名健康志愿者（对照组）于入组时检查血清 S‐100β水平，对检测结果进行对比分析。结果重度梗死组各时点血清 S‐100β蛋白水平显著高于其他3组（P＜0．01），中度梗死组各时点血清 S‐100β蛋白水平显著高于轻度梗死组及对照组（P＜0．01），轻度梗死组各时点血清 S‐100β蛋白水平显著高于对照组（P＜0．01）。3组患者3 d 内血清 S‐100β蛋白水平持续升高，3 d 后持续降低。结论脑梗死患者血清 S‐100β蛋白水平明显升高，可作为评定脑梗死患者病情变化及严重程度的生化指标。